Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial

The Lancet

Volumn 375, Issue 9717, 2010, Pages 816-823

  Nout, RA ^a   Smit, VTHBM ^a   Putter, H ^a   Jürgenliemk Schulz, IM ^b   Jobsen, JJ ^c   Lutgens, LCHW ^d   van der Steen Banasik, EM ^e   Mens, JWM ^f   Slot, A ^g   Kroese, MC Stenfert ^h   van Bunningen, BNFM ⁱ   Ansink, AC ^f   van Putten, WLJ ^f   Creutzberg, CL ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Arnhems Radiotherapeutisch Instituut   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Radiotherapy Institute Friesland   (Netherlands)

^h Radiotherapy Institute Stedendriehoek en Omstreken   (Netherlands)

ⁱ NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATROPHY; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENDOMETRIUM CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTERMETHOD COMPARISON; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NETHERLANDS; OPEN STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; VAGINAL BRACHYTHERAPY;

EID: 77649130174     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)62163-2     Document Type: Article

References (23)

1. Bray F., Loos A.H., Oostindier M., and Weiderpass E. Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre- and postmenopausal women in Europe. Int J Cancer 117 (2005) 123-131
2. Creutzberg C.L., van Putten W.L.J., Koper P.C.M., et al., for the PORTEC Study Group. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet 355 (2000) 1404-1411
3. Scholten A.N., van Putten W.L., Beerman H., et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 63 (2005) 834-838
4. Keys H.M., Roberts J.A., Brunetto V.L., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004) 744-751
5. Creutzberg C.L., van Putten W.L., Koper P.C., et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys 51 (2001) 1246-1255
6. Alektiar K.M., Venkatraman E., Chi D.S., and Barakat R.R. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys 62 (2005) 111-117
7. Anderson J.M., Stea B., Hallum A.V., Rogoff E., and Childers J. High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer. Int J Radiat Oncol Biol Phys 46 (2000) 417-425
8. Chadha M., Nanavati P.J., Liu P., Fanning J., and Jacobs A. Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecol Oncol 75 (1999) 103-107
9. Rittenberg P.V., Lotocki R.J., Heywood M.S., and Krepart G.V. Stage II endometrial carcinoma: limiting post-operative radiotherapy to the vaginal vault in node-negative tumors. Gynecol Oncol 98 (2005) 434-438
10. Weiss E., Hirnle P., Arnold-Bofinger H., Hess C.F., and Bamberg M. Adjuvant vaginal high-dose-rate afterloading alone in endometrial carcinoma: patterns of relapse and side effects following low-dose therapy. Gynecol Oncol 71 (1998) 72-76
11. Nout R.A., Putter H., Jurgenliemk-Schulz I.M., et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 27 (2009) 3547-3556
12. Shepherd J.H. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 96 (1989) 889-892
13. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
14. Scholten A.N., Smit V.T., Beerman H., van Putten W.L., and Creutzberg C.L. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 100 (2004) 764-772
15. Lax S.F., Kurman R.J., Pizer E.S., et al. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pahtol 24 (2000) 1201-1208
16. Putter H., Fiocco M., and Geskus R.B. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26 (2007) 2389-2430
17. Aalders J., Abeler V., Kolstad P., and Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56 (1980) 419-427
18. The ASTEC/EN.5 writing committee on behalf of the ASTEC/EN.5 Study Group. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373 (2009) 137-146
19. Benedetti P.P., Basile S., Maneschi F., et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100 (2008) 1707-1716
20. The writing committee on behalf of the ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373 (2009) 125-136
21. National Cancer Institute. Cancer Therapy Evaluation Program, common terminology criteria for adverse events, Version 3.0 (August, 2006). http://ctep.cancer.gov (accessed June 19, 2009).
22. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 (2003) 176-181
23. Lindau S.T., Schumm L.P., Laumann E.O., Levinson W., O'Muircheartaigh C.A., and Waite L.J. A study of sexuality and health among older adults in the United States. N Engl J Med 357 (2007) 762-774